alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015302EN.01005201.xml

| 14.9.2015 | EN | Official Journal of the European Union | C 302/52 |
| --- | --- | --- | --- |

14.9.2015

EN

Official Journal of the European Union

C 302/52

---

Judgment of the General Court of 15 July 2015 — Rouffaud v EEAS

(Case T-457/14 P) (1)

1

((Appeal - Civil Service - Auxiliary member of contract staff - Reclassification of contract - Rule of correspondence between the application and the complaint - Article 91(2) of the Staff Regulations of Officials))

(2015/C 302/67)

Language of the case: French

Parties

Parties

Appellant: Thierry Rouffaud (Brussels, Belgium) (represented by: initially M. de Abreu Caldas, D. de Abreu Caldas and J. N. Louis, then J. N. Louis and N. de Montigny, lawyers)

Appellant:

Other party to the proceedings: European External Action Service (EEAS) (represented by: S. Marquardt and M. Silva, acting as Agents)

Other party to the proceedings:

Re:

Re:

Appeal against the judgment of the European Union Civil Service Tribunal (Third Chamber) of 9 April 2014 in Rouffaud v EEAS (F-59/13, ECR-SC, EU:F:2014:49), and seeking to have that judgment set aside.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Sets aside the judgment of European Union Civil Service Tribunal (Third Chamber) of 9 April 2014 in Rouffaud v EEAS (F-59/13, ECR-SC, EU:F:2014:49); |
| --- | --- |

1.

Sets aside the judgment of European Union Civil Service Tribunal (Third Chamber) of 9 April 2014 in Rouffaud v EEAS (F-59/13, ECR-SC, EU:F:2014:49);

| 2. | Refers the case back to the Civil Service Tribunal; |
| --- | --- |

2.

Refers the case back to the Civil Service Tribunal;

| 3. | Reserves the costs. |
| --- | --- |

3.

Reserves the costs.

---

(1)  OJ C 261, 11.8.2014.

1

---
I 

118TH CONGRESS 

2D SESSION H. R. 7288 

To repeal Freedom Support Act section 907 waiver authority with respect 

to assistance to Azerbaijan. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 7, 2024 

Mr. LAWLER (for himself, Mr. PALLONE, Mr. BILIRAKIS, and Mr. AMO) introduced the following bill; which was referred to the Committee on Foreign 

Affairs 

A BILL 

To repeal Freedom Support Act section 907 waiver authority 

with respect to assistance to Azerbaijan. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Armenian Protection 

5 Act of 2024’’. 

6 SEC. 2. FREEDOM SUPPORT ACT SECTION 907 WAIVER RE7 PEAL. 

8 The President may not exercise the waiver authority 

9 provided pursuant to title II of the Foreign Operations, 

10 Export Financing, and Related Programs Appropriations 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7288 IH

1 Act, 2002 (Public Law 107–115) (22 U.S.C. 5812 note), 

2 under the heading ‘‘ASSISTANCE FOR THE INDEPENDENT

3 STATES OF THE FORMER SOVIET UNION’’ under subsection 

4 (g), with respect to amounts appropriated or otherwise 

5 made available for fiscal year 2024 or 2025. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
1 

### Green, David A.
From: Boyd.Rochelle@epamail.epa.gov Sent: Tuesday, October 19, 2010 1:11 PM To: bcaffee@arg-scrap.com Subject: Trip Report
Hi Ben, this is a courtesy e

- mail letting you know that the trip report that we sent back for you to review will be classified as non - CBI and is considered to be an accurate account of your aluminum operations. Comments were due back to our office on Octo ber 8, 2010. Thanks

Rochelle Boyd, Environmental Engineer U.S. Environmental Protection Agency Office of Air Quality Planning and Standards Sector Policies and Programs Division 109 T.W. Alexander Drive, RTP, NC 27711 Mail Drop D243

- 02 Ph: (919) 541

- 1390 Fax: (919) 541

- 3207 Email: boyd.rochelle@epa.gov
§ 74.3710 D&C Yellow No. 10. ( a ) *Identity.* The color additive D&C Yellow No. 10 shall conform to the identity requirements of § 74.1710(a).
( b ) *Specifications.* The color additive D&C Yellow No. 10 for use in contact lenses shall conform to the specifications of § 74.1710(b).
( c ) *Uses and restrictions.* ( 1 ) The color additive D&C Yellow No. 10 may be used for coloring contact lenses in amounts not to exceed the minimum reasonably required to accomplish the intended coloring effect.
( 2 ) Authorization for this use shall not be construed as waiving any of the requirements of sections 510(k), 515, and 520(g) of the Federal Food, Drug, and Cosmetic Act with respect to the contact lens in which the color additive is used.
( d ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Yellow No. 10 shall be certified in accordance with regulations in part 80 of this chapter.
[52 FR 28690, Aug. 3, 1987]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7607 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
118th CONGRESS
  2d Session
                                H. R. 7607

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at Block 1025, Lots 18 & 19, Northeast Corner of US Route 9 South and 
Main Street in the Township of Middle, County of Cape May, New Jersey, 
          as the ``George Henry White Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. GEORGE HENRY WHITE POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at Block 1025, Lots 18 & 19, Northeast Corner of US Route 9 
South and Main Street in the Township of Middle, County of Cape May, 
New Jersey, shall be known and designated as the ``George Henry White 
Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``George 
Henry White Post Office Building''.

            Passed the House of Representatives June 3, 2024.

            Attest:

                                                                 Clerk.
118th CONGRESS

  2d Session

                               H. R. 7607

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
 at Block 1025, Lots 18 & 19, Northeast Corner of US Route 9 South and 
Main Street in the Township of Middle, County of Cape May, New Jersey, 
          as the ``George Henry White Post Office Building''.
```
Editorial Note on Part 328
Editorial Note: Nomenclature changes to part 328 appear at 69 FR 13717, Mar. 24, 2004.

§ 328.50 Principal display panel of all OTC drug products intended for oral ingestion that contain alcohol. ( a ) The amount (percentage) of alcohol present in a product shall be stated in terms of percent volume of absolute alcohol at 60 °F (15.56 °C) in accordance with § 201.10(d)(2) of this chapter.
( b ) A statement expressing the amount (percentage) of alcohol present in a product shall appear prominently and conspicuously on the “principal display panel,” as defined in § 201.60 of this chapter. For products whose principal display panel is on the immediate container label and that are not marketed in another retail package (e.g., an outer box), the statement of the percentage of alcohol present in the product shall appear prominently and conspicuously on the “principal display panel” of the immediate container label.
( c ) For products whose principal display panel is on the retail package and the retail package is not the immediate container, the statement of the percentage of alcohol present in the product shall also appear on the immediate container label; it may appear anywhere on that label in accord with section 502(e) of the Federal Food, Drug, and Cosmetic Act.
( d ) The statement expressing the amount (percentage) of alcohol present in the product shall be in a size reasonably related to the most prominent printed matter on the panel or label on which it appears, and shall be in lines generally parallel to the base on which the package rests as it is designed to be displayed.
( e ) For a product to state in its labeling that it is “alcohol free,” it must contain no alcohol (0 percent).
( f ) For any OTC drug product intended for oral ingestion containing over 5 percent alcohol and labeled for use by adults and children 12 years of age and over, the labeling shall contain the following statement in the directions section: “Consult a physician for use in children under 12 years of age.”
( g ) For any OTC drug product intended for oral ingestion containing over 0.5 percent alcohol and labeled for use by children ages 6 to under 12 years of age, the labeling shall contain the following statement in the directions section: “Consult a physician for use in children under 6 years of age.”
( h ) When the direction regarding age in paragraph (e) or (f) of this section differs from an age-limiting direction contained in any OTC drug monograph in this chapter, the direction containing the more stringent age limitation shall be used.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Consolidated Financial Statements at December 31, 1997 Audited and is
qualified its entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       2,594,312
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             2,644,392
<PP&E>                                          79,566
<DEPRECIATION>                                  31,920
<TOTAL-ASSETS>                               2,906,737
<CURRENT-LIABILITIES>                          463,617
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       120,986
<OTHER-SE>                                   2,322,134
<TOTAL-LIABILITY-AND-EQUITY>                 2,906,737
<SALES>                                              0
<TOTAL-REVENUES>                                83,618
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             4,818,093
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (4,734,475)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (4,734,475)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (4,734,475)
<EPS-PRIMARY>                                   (0.43)
<EPS-DILUTED>                                   (0.43)
        

</TABLE>
# C_2015190EN.01001402.xml

| 8.6.2015 | EN | Official Journal of the European Union | C 190/14 |
| --- | --- | --- | --- |

8.6.2015

EN

Official Journal of the European Union

C 190/14

---

Judgment of the General Court of 16 April 2015 — Drogenhilfe Köln Projekt v OHIM (Rauschbrille)

(Case T-319/14) (1)

((Community trade mark - Application for Community word mark Rauschbrille - Absolute grounds for refusal - Descriptiveness - Lack of distinctive character - Article 7(1)(b) and (c) of Regulation (EC) No 207/2009))

(2015/C 190/17)

Language of the case: German

Parties

Applicant: Drogenhilfe Köln Projekt gGmbH (Cologne, Germany) (represented by: V. Schoene, lawyer)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: G. Schneider, Agent)

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 29 January 2014 (Case R 1356/2013-1), concerning an application for registration of the word sign Rauschbrille as a Community trade mark.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Drogenhilfe Köln Projekt gGmbH to pay the costs. |
| --- | --- |

2.

Orders Drogenhilfe Köln Projekt gGmbH to pay the costs.

---

(1)  
  OJ C 212, 7.7.2014.

---
#### § 660.31 Eligibility of donor.

Donors of peripheral blood for Reagent Red Blood Cells must meet all the criteria for donor eligibility under §§ 630.10 and 630.15 of this chapter.

[80 FR 29906, May 22, 2015]
# C_2016027EN.01004701.xml

| 25.1.2016 | EN | Official Journal of the European Union | C 27/47 |
| --- | --- | --- | --- |

25.1.2016

EN

Official Journal of the European Union

C 27/47

---

Judgment of the General Court of 26 November 2015 — Junited Autoglas Deutschland v OHIM — United Vehicles (UNITED VEHICLEs)

(Case T-404/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community word mark UNITED VEHICLEs - Earlier Community word mark Junited - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2016/C 027/58)

Language of the case: German

Parties

Parties

Applicant: Junited Autoglas Deutschland GmbH & Co. KG (Cologne, Germany) (represented by: C. Weil, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: D. Walicka, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: United Vehicles GmbH (Munich, Germany)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 7 April 2014 (Case R 859/2013-4) relating to opposition proceedings between Junited Autoglas Deutschland GmbH & Co. KG and United Vehicles GmbH.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Junited Autoglas Deutschland GmbH & Co. KG to pay the costs. |
| --- | --- |

2.

Orders Junited Autoglas Deutschland GmbH & Co. KG to pay the costs.

---

(1)  OJ C 292, 1.9.2014.

1

---
<PAGE>






                                                                    Exhibit 23.1


               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

         We consent to the incorporation by reference in this Annual Report
(Form 10-K) of Mackie Designs Inc. of our report dated February 10, 1998
included in the 1997 Annual Report to Shareholders of Mackie Designs Inc.

         Our audits also included the financial statement schedule of Mackie
Designs Inc. listed in Item 14(a). This schedule is the responsibility of the
Company's management. Our responsibility is to express an opinion based on our
audits. In our opinion, the financial statement schedule referred to above, when
considered in relation to the basic consolidated financial statements taken as a
whole, presents fairly in all material respects the information set forth
therein.

         We also consent to the incorporation by reference in the
Registration Statement (Form S-8 No. 33-98720) pertaining to the 1995 Stock
Option Plan of Mackie Designs Inc. of our report dated February 10, 1998 with
respect to the consolidated financial statements incorporated herein by
reference, and our report included in the preceding paragraph with respect to
the financial statement schedule included in this Annual Report (Form 10-K)
of Mackie Designs Inc.

                                     Ernst & Young LLP


Seattle, Washington
March 31, 1998



                                       97
# C_2015065EN.01001802.xml

| 23.2.2015 | EN | Official Journal of the European Union | C 65/18 |
| --- | --- | --- | --- |

23.2.2015

EN

Official Journal of the European Union

C 65/18

---

Request for a preliminary ruling from the Supremo Tribunal de Justiça (Portugal) lodged on 13 November 2014 — P v M

(Case C-507/14)

(2015/C 065/27)

Language of the case: Portuguese

Referring court

Referring court

Supremo Tribunal de Justiça

Parties to the main proceedings

Parties to the main proceedings

Applicant: P

Applicant:

Defendant: M

Defendant:

Question referred

Question referred

‘Where a case concerning parental responsibility is brought in one Member State and another case, in which the same cause of action is at issue, has been brought at an earlier point in time in a different Member State and which has since been stayed at the request of the applicant in that case, without having been served on the relevant defendant and without the latter having been informed of its existence or having participated in that case in any way, and which was still stayed at the time the defendant in the earlier case brought the subsequent proceedings, can it be deemed, in the light of Article 16(1)(a) of Council Regulation (EC) No 2201/2003 (1) of 27 November 2003 and for the purposes of Article 19(2) of that regulation, that the court before which the earlier proceedings were stayed was the first court to be seised?’

1

---

(1)  Council Regulation (EC) No 2201/2003 of 27 November 2003 concerning jurisdiction and the recognition and enforcement of judgments in matrimonial matters and the matters of parental responsibility, repealing Regulation (EC) No 1347/2000 — (OJ 2003 L 338, p. 1).

1

---
§ 582.3845 Stannous chloride. ( a ) *Product.* Stannous chloride.
( b ) *Tolerance.* This substance is generally recognized as safe for use at a level not exceeding 0.0015 percent calculated as tin in accordance with good manufacturing or feeding practice.
[Federal Register Volume 76, Number 2 (Tuesday, January 4, 2011)]
[Notices]
[Page 369]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-33230]



[[Page 369]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Neurological Disorders and Stroke; Notice 
of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Neurological Disorders 
and Stroke Initial Review Group, NST-1 Subcommittee.
    Date: January 31-February 1, 2011.
    Time: 8 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites Hotel, 1250 22nd Street, NW., Washington, 
DC 20037.
    Contact Person: Raul A. Saavedra, PhD, Scientific Review 
Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience 
Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 
20892-9529. 301-496-9223. <a href="/cdn-cgi/l/email-protection#8ffceeeef9eaebfdfdcfe1e6e1ebfca1e1e6e7a1e8e0f9"><span class="__cf_email__" data-cfemail="5e2d3f3f283b3a2c2c1e3037303a2d7030373670393128">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, 
Clinical Research Related to Neurological Disorders; 93.854, 
Biological Basis Research in the Neurosciences, National Institutes 
of Health, HHS)

    Dated: December 27, 2010.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-33230 Filed 1-3-11; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 640.81 Processing. ( a ) *Date of manufacture.* The date of manufacture shall be the date of final sterile filtration of a uniform pool of bulk solution.
( b ) *Processing method.* The processing method shall not affect the integrity of the product, and shall have been shown to yield consistently a product which is safe for intravenous injection.
( c ) *Microbial contamination.* All processing steps shall be conducted in a manner to minimize the risk of contamination from microorganisms, pyrogens, or other impurities. Preservatives to inhibit growth of microorganisms shall not be used during processing.
( d ) *Storage of bulk fraction.* Bulk concentrate to be held more than 1 week prior to further processing shall be stored in clearly identified closed vessels at a temperature of −5 °C or colder. Any other bulk form of the product, exclusive of the sterile bulk solution, to be held more than 1 week prior to further processing shall be stored in clearly identified closed vessels at a temperature of 5 °C or colder. Any bulk fraction to be held one week or less prior to further processing shall be stored in clearly identified closed vessels at a temperature of 5 °C or colder.
( e ) *Heat treatment.* Heating of the final containers of Albumin (Human) shall begin within 24 hours after completion of filling. Heat treatment shall be conducted so that the solution is heated continuously for not less than 10, or more than 11 hours, at an attained temperature of 60±0.5 °C.
( f ) *Stabilizer.* Either 0.08±0.016 millimole sodium caprylate, or 0.08±0.016 millimole sodium acetyltryptophanate and 0.08±0.016 millimole sodium caprylate per gram of protein shall be present as a stabilizer(s). Calculations of the stabilizer concentration may employ the labeled value for the protein concentration of the product as referred to in § 640.84(d).
( g ) *Incubation.* All final containers of Albumin (Human) shall be incubated at 20 to 35 °C for at least 14 days following the heat treatment prescribed in paragraph (e) of this section. At the end of this incubation period, each final container shall be examined and all containers showing any indication of turbidity or microbial contamination shall not be issued. The contents of turbid final containers shall be examined microscopically and tested for sterility. If growth occurs, organisms shall be identified as to genus, and the material from such containers shall not be used for further manufacturing.
[42 FR 27582, May 31, 1977, as amended at 50 FR 4140, Jan. 29, 1985; 64 FR 26286, May 14, 1999; 65 FR 13679, Mar. 14, 2000; 65 FR 52018, Aug. 28, 2000]